A factorial trial protocol planned to compare remimazolam and other sedatives with three analgesic adjuncts. It supplied a study design, not evidence of which combination reduced fatigue.
The proposed single-center study would allocate 315 adults to nine combinations formed from propofol, ciprofol, or remimazolam and sufentanil, esketamine, or lidocaine. The planned primary outcome was a patient-reported fatigue score thirty minutes after endoscopy.
The protocol separately defined a composite safety outcome involving hypotension and hypoxemia and planned main-effect analyses of sedative and adjunct choices.
The authors acknowledged that the trial was underpowered for interactions between drug pairs. Any suggested synergy would therefore be exploratory. The protocol also did not include long-term fatigue, return to work, or cost-utility outcomes.
No completed treatment-group results were presented in this supplied paper. Planned enrollment and statistical power are not observed sample size or demonstrated benefit.
Keep early subjective fatigue separate from awakening, discharge readiness, and psychomotor recovery. This paper can explain how investigators intend to compare regimens. It cannot support claiming that remimazolam already reduced fatigue or that a particular combination proved safest in the planned trial.
Original analysis of the supplied journal article, identified as PMC12863068.